Will Lower Prices Reshape Health Coverage?
Prescription weight-loss treatments like Wegovy and Ozempic have made many headlines over the past few years, and they’ve gotten almost as much attention for their high cost as they have for their popularity. The price tags associated with these medications have put them out of reach for many Americans, especially when insurance doesn’t cover them.
But that may be changing.
A recent survey from eHealth suggests that 33% of U.S. adults would consider using these treatments for weight loss and diabetes management if prices come down. That’s on top of the 5.1% of adults already using them to help manage weight today.
So what does that mean for consumers, employers, and the future of health spending? Let’s break it down.
What Are GLP-1s and Why Are They Popular?
Wegovy, Ozempic, and Mounjaro are a class of medications called GLP-1 agonists. They mimic a hormone that regulates blood sugar and appetite. Originally developed for diabetes management, they’ve quickly gained traction for their ability to support significant weight loss.
With over 74% of American adults classified as overweight or obese, demand is growing rapidly, and not just for weight loss but for long-term health improvement and chronic disease prevention.
According to a RAND survey,
- 12% of U.S. adults have already tried a GLP-1 medication
- Another 26% said they’re interested in trying them
This reflects a broader trend toward medical-based weight management, as more Americans seek alternatives to traditional diet and exercise-only strategies.
The Price Barrier
One of the biggest obstacles to accessing these medications has been cost.
GLP-1 drugs can easily run $900–$1,300 per month without insurance. But eHealth’s data suggests that many Americans would be willing to pay out of pocket if prices were reduced.
Here’s what the eHealth survey revealed about consumer willingness to pay:
- 31% said they would spend more than $300/month
- 19% said they’d only pay up to $50/month
- And 33% said they would try a GLP-1 once the price drops
If just one-third of U.S. adults were to spend an average of $200/month on these drugs, out-of-pocket spending could skyrocket to $220 billion annually. That’s a five-time increase over the $45 billion spent in 2024.
What This Means for Health Plans and Insurance
This rising interest in GLP-1 medications isn’t just a personal health story — it’s a benefits and insurance story, too.
Many health plans currently exclude coverage for weight-loss drugs, viewing them as lifestyle choices rather than essential care. But growing clinical evidence supporting their long-term health impact may shift that approach.
Already, some employers and insurers are reconsidering their stance, especially as they weigh:
- Cost vs. benefit: Could covering GLP-1s reduce long-term healthcare expenses related to obesity, diabetes, and heart disease?
- Workforce productivity and retention: Could access to these medications improve employee energy and absenteeism rates and boost competitiveness?
And with lower 2026 premiums surprising 23% of survey participants, there's also a clear message that consumers are paying closer attention to how healthcare dollars are spent, and where added value may come from.
The Bottom Line
GLP-1 weight-loss medications represent a significant movement in how Americans approach chronic disease and personal health. As costs potentially come down and insurance models evolve, these drugs may soon move from luxury to mainstream.
For individuals, now is the time to:
- Understand if and how GLP-1 coverage fits into your current health plan
- Track how your insurer approaches future benefit changes
- Speak with your healthcare provider about safe, personalized weight management options
For employers and brokers, it’s time to start thinking about how to integrate medical weight-loss solutions into plan design, especially as consumer demand continues to grow.
Have questions about what your current health plan covers, or how to expand access to weight-loss medications in future benefit packages? We’re here to help you navigate what’s next.
